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Percutaneous transluminal aortic valvuloplasty was per- 
formed on 125 patients (59 men [47%], mean age 76 f 13 
years) between July 1986 and May 1988, with presenting 
symptoms of severe congestive heart failure in 88 (70%), 
moribund state in 15 (12%) and syncope in 17 (14%). 
Surgical valve replacement was considered unsuitable in 
79% of cases. A multiple balloon technique was utilized in 
119 patients (95%). 
Valvuloplasty produced significant changes in peak 
pressure gradient (87 -C 38 to 32 2 17 mm Hg), mean 
pressure gradient (70 -C 26 to 30 f 13 mm Hg) and valve 
area (0.6 f 0.2 to 1.0 -C 0.3 cm*). Complications included: 
in-hospital mortality in 10% (6 of 13 deaths in moribund 
patients), neurologic deficit in 3% and myocardial infarc- 
tion in 2%. Arterial repair was required at 12 (4%) of 325 
entry sites. 
Multivariate analysis identified severe congestive heart 
failure, preprocedure left ventricular ejection fraction and 
cardiac output as the only independent variables signifi- 
cantly affecting mortality. The cumulative probability of 
survival at 12 months was 62 f 6% and, excluding non- 
cardiac deaths, was 77 It 5%. At a mean of 12 + 4 months’ 
follow-up, 55 of 72 patients were symptomatically im- 
proved; 10 patients with symptom recurrence underwent 
repeat valvuloplasty and 5 had valve replacement. Cardiac 
catheterization was repeated in 12 symptomatically im- 
proved patients, 9 of whom had valve restenosis. 
These data indicate that aortic valvuloplasty should be 
considered a palliative therapy for elderly patients with 
symptomatic calcific aortic stenosis who are poor surgical 
candidates. 
(J Am Co11 Cardiol1989;14:1210-7) 
Aortic valvuloplasty (l), an attempted reparative, open 
surgical procedure requiring thoracotomy and cardiopulmo- 
nary bypass, was abandoned because of disappointing he- 
modynamic results and a high recurrence rate (2). Recently, 
this surgical technique was revived for selected patients (3), 
although still remaining a controversial procedure (4). The 
initial success achieved with percutaneous balloon aortic 
valvuloplasty in geriatric patients stimulated its application, 
primarily in elderly patients with terminal degenerative 
calcific aortic stenosis (5-18) who have a significantly in- 
creased operative risk from aortic valve replacement. This 
report describes our experience with 125 patients, the ma- 
jority of whom were treated with multiple balloon valvulo- 
plasty, the procedural characteristics of the technique, the 
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early outcome of the patients and patient follow-up, includ- 
ing the cardiac catheterization data available in symptomat- 
ically improved patients. 
Methods 
Study patients. Between July 1986 and May 1988, aortic 
valvuloplasty was performed on 125 symptomatic patients 
with severe aortic stenosis (aortic valve area ~0.8 cm2 or an 
aortic valve area index of ~0.4 cm2/m2) with either conges- 
tive heart failure, syncope or angina. All patients gave 
informed consent for the investigational valvuloplasty pro- 
cedure after explanation of the alternative therapies, poten- 
tial risks and complications. The procedure was performed 
according to a protocol reviewed and approved by the 
Institutional Review Board of St. Luke’s Medical Center. 
All patients with severe aortic stenosis were accepted 
into the protocol, whether or not they were moribund (15 
patients [12%]). In fact, when the baseline measurement of 
the pulmonary mixed venous oxygen saturation was ~40% 
or if the left ventricular ejection fraction was <35%, indicat- 
ing hemodynamic compromise, the patient was electively 
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intubated before the procedure to provide the best oxygen- 
ation during the cardiac output compromise with balloon 
inflation. Twelve patients were intubated during the proce- 
dure: 2 patients with a tracheotomy had required mechanical 
ventilation, 6 were electively intubated before and 4 required 
intubation during the procedure. 
Technique. A cutdown was performed in the right ante- 
cubital fossa to isolate the cephalic vein and brachial artery. 
Right heart catheterization was performed using a flow- 
directed thermodilution fiberoptic catheter (P7110 Opticath, 
Oximetric, Inc.) (7). This catheter remained in the pulmo- 
nary artery for continuous monitoring of mixed venous 
oxygen saturation and provided assessment of patient recov- 
ery after balloon inflation. The right (or left) femoral artery 
and vein were cannulated with a 9F and 8F sidearm sheath, 
respectively. A 6F arterial sheath was percutaneously in- 
serted into the left brachial artery, through which a 6F 
catheter was placed into the ascending aorta to continuously 
monitor aortic pressure. A supravalvular aortogram in the 
left anterior oblique view was performed with dynamic 
digital subtraction angiography to assess the degree of aortic 
insufficiency. 
Transseptal catheterization was performed with use of a 
Mullins transseptal sheath with sidearm (USCI). After the 
transseptal sheath was placed into the left atrium, a Dorros- 
Babic 7.5F flow-directed catheter (Baxter-Edwards Labora- 
tories) inflated with carbon dioxide was floated into the left 
ventricle. 
Through a right urteriotomy, after heparin (3,000 to 5,000 
U) was injected distally into the artery, an 8 French multi- 
purpose catheter was placed into the ascending aorta. Once 
all catheters (ascending aorta, left ventricular and pulmonary 
artery) were in place, the transvalvular pressure gradient and 
thermodilution cardiac output were recorded. A pulmonary 
artery blood sample was obtained for calibration of the 
Oximetric catheter for continuous on-line recording of mixed 
venous oxygen saturation. The simultaneously recorded left 
ventricular and aortic pressures were used to calculate the 
computer-generated mean and peak transvalvular pressure 
gradients and aortic valve area. The pressures from the 
ascending aortic (left brachial) and left ventricular (transsep- 
tally placed) catheters were continuously recorded, even 
during balloon inflation. 
With the retrograde technique, the uortic valve wus 
crossed with the hruchiul and femoral artery catheters. A 
260 cm long, 0.035 in. (0.089 cm) external diameter Amplatz 
exchange wire with an exaggerated pigtail curve was ad- 
vanced through the catheters into the left ventricle. The 
catheters were removed and, with the exchange wires re- 
maining in the left ventricle, a Valvex TM (USCI) on 8F, 125 
cm catheter with a 15 or 20 mm diameter balloon, 5 cm in 
length, was advanced and positioned across the aortic valve 
and inflated with a 20% contrast agent-saline solution mix- 
ture until loss of the balloon waist was achieved. The 20 mm 
Valvex balloon catheter was easily inserted into the brachial 
artery through a longitudinal arteriotomy, and when the 
catheter was utilized femorally, a 1OF arterial sheath was 
required. Occasionally 15, 18, 20 or 23 mm balloon catheters 
(Mansfield Scientific) were utilized; these were too large (9F 
and 10F) for facile use in the brachial artery, and required a 
12F or 14F sheath when utilized femorally. The inflation/ 
deflation cycle lasted between 20 and 60 s. The balloon- 
deflated catheters were retracted back into the ascending 
aorta, leaving the guide wires in the ventricle. During the 
inflation/deflation cycle, aortic and left ventricular pressures 
and mixed venous oxygen saturation were continuously 
recorded. A subsequent dilation, if necessary, was per- 
formed only when the mixed venous oxygen saturation had 
returned to baseline value (usually between 45% and 60%). 
The simultaneous pressure recordings permitted immediate 
assessment of the adequacy of the dilation and, in conjunc- 
tion with thermodilution cardiac output, allowed rapid com- 
puter calculation of the valve area. These data determined 
the need for any further dilations with larger valvuloplasty 
catheters. 
Single, double and triple balloon valvuloplasty. Six pa- 
tients underwent single balloon aortic valvuloplasty: the 
initial four patients of the series and two patients in whom 
arterial access prevented more than one balloon catheter 
from being utilized. The remaining 119 patients underwent a 
multiple balloon technique, primarily with two simultaneous 
balloons. When the results of double balloon valvuloplasty 
were not satisfactory and the balloon sizes were considered 
maximal for the echocardiographically measured aortic 
valve anulus (19) (balloon area to aortic anulus area ratio 
5 I. I), a triple balloon technique was utilized. This approach 
was undertaken to decrease the incidence of aortic anulus 
tear and to decrease the possibility of creating or worsening 
aortic insufficiency. A third balloon catheter (a 7F USC1 
PE-Plus, 125 cm catheter with an 8, 10 or 12 mm balloon) 
was placed across the valve and simultaneously inflated with 
the other two balloons. The third transvalvular catheter 
introduction was usually performed through the left femoral 
artery where the aortic valve was retrogradely crossed; the 
other two balloon catheters lay in the ascending aorta, with 
the two exchange wires remaining in the left ventricle. This 
modification of technique was utilized in 19 patients after the 
double balloon failed to achieve a satisfactory aortic valve 
area (>0.75 cm2), while efforts were made to avoid the 
uneven and excessive stretching (shearing) forces applied to 
the aortic anulus when the summated balloon sizes exceeded 
the annular dimension. Theoretically, the two balloons cre- 
ated an oval pressure deformation to the anulus, whereas the 
addition of the third balloon converted the oval to more 
circular forces. These modifications resulted in a larger valve 
area than that created by the two balloons and avoided any 
annular tears (20). 
After the postvalvuloplasty measurements were obtained 
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and were considered to be satisfactory (aortic valve area 
>0.9 cm2) or when larger balloons were considered detri- 
mental (19,21), a supravalvular aortogram was repeated. The 
brachial catheters were removed and the artery repaired. 
The patient was transferred to the intensive care unit for 
observation with the pulmonary catheter and femoral artery 
sheaths in place. The arterial and venous sheaths were 
removed within 12 h. The patient was mobilized within 24 to 
48 h and discharged when clinically indicated. 
Definitions. An early death was defined as perioperative 
(within 24 h of the procedure) and a late death occurred 
between 24 h and 30 days after valvuloplasty. Late onset 
aortic insufficiency was defined as a worsening by more than 
one angiographic grade of the degree of aortic insufficiency 
as determined from the follow-up aortogram. Recurrence of 
symptoms was defined as a reappearance of the same 
complaints with or without life-style impairment in patients 
who had improved after valvuloplasty. A procedure was 
considered successful when the valve area was dilated >25% 
and the patient survived or did not undergo emergency valve 
replacement. 
Follow-up. Follow-up information (September 1988) was 
obtained in 100% of surviving patients through office ap- 
pointments, or contact with the attending physician, or both. 
Mean follow-up time was 12.3 + 4 months for the 112 
patients discharged. 
Statistical analysis. All values were expressed as mean 
values ? SD. Statistical analysis was performed with a 
chi-square test to assess differences in categorical variables 
and Student’s t test for continuous variables. Multivariate 
analysis was performed using logistic regression to evaluate 
clinical (age, gender, degree of congestive heart failure, renal 
disease, prior documented myocardial infarction, diabetes, 
hypertension and chronic pulmonary disease) and hemody- 
namic (left ventricular ejection fraction, cardiac output, pre- 
and postpeak and mean aortic valve gradient and area and 
percent change in cardiac output, valve gradient and valve 
area) factors influencing success and survival (22). Life 
tables were derived using published techniques (21). 
Results 
Patient characteristics (Tables 1 and 2). There were 125 
patients with a mean age of 76 years, many of whom had 
significant concomitant medical problems in addition to their 
advanced age (100 patients [80%] were >70 years, and 51 
[41%] X30 years). The primary presenting symptom (Table 
2) was congestive heart failure (82%); the major reason for 
patient referral was old age (41%). The mean left ventricular 
ejection fraction calculated by a multigated nuclear angio- 
gram obtained at rest before valvuloplasty was 57 2 21% 
(range 12% to 90%). A left ventricular ejection fraction of 
~30% was present in 18 patients (lo%), and 25 patients 
(20%) had an ejection fraction of ~40%. 
Table 1. Clinical Characteristics of 125 Patients 
Gender 
Male 
Female 
Age (yr) 
Mean 
Range 
Prior CABG 
Severe COPD 
Cancer 
Severe bleeding disorder 
Prior stroke 
50 (47%) 
66 (53%) 
76 213 
37-94 
7 (6%) 
16 (13%) 
16 (13%) 
8 (6%) 
12 (10%) 
CABG = coronary artery bypass surgery; COPD = chronic obstructive 
pulmonary disease. 
Angiographic and hemodynamic data (Table 3). The val- 
vuloplasty procedure was performed successfully in 111 
(89%) of 125 patients; 11 patients had ~25% increase in 
aortic valve area. Coronary arteriography demonstrated 
normal or nonobstructive disease (~50% diameter stenosis) 
in 76% of patients. The peak pressure gradient was reduced 
from 87 rt 38 to 32 ? 17 mm Hg (p < 0.001) and aortic valve 
area increased from 0.6 ? 0.2 to 1.0 + 0.3 cm2 (p < 0.001). 
Cardiac output remained stable after the procedure (before 
4.3 + 1.5 and after 4.6 ? 1.3 literslmin; p = NS). 
A signi$cant increase in the degree of aortic insuficiency 
occurred in four patients treated with the double balloon 
technique (3%); two were treated surgically because of 
aortic annular tear (22) and two were treated medically. In 
16 patients (13%) the degree of aortic insufficiency in- 
creased by one angiographic grade without hemodynamic 
significance. In six patients (5%), the degree of aortic insuf- 
ficiency decreased by at least one angiographic degree. 
Hospital course (Table 4). Death occurred in the cardiac 
catheterization laboratory in three patients because of elec- 
tromechanical dissociation during the first inflation in two 
moribund patients with severe left ventricular dysfunction, 
and refractory ventricular fibrillation in one patient. Before 
hospital discharge, an additional 10 patients died, including 6 
Table 2. Preoperative Clinical Data From 125 Patients 
Primary presenting symptoms 
Congestive heart failure 
Terminal heart failure (moribund) 
Congestive heart failure (class II to IV) 
Syncope 
Angina 
Reasons for referral 
Refused for surgery 
Old age (280 yr) 
Moribund 
Surgically high risk 
Prior stroke 
Self referral 
103 (82%) 
15 (12%) 
88 (70%) 
17 (14%) 
5 (4%) 
18 (14%) 
51 (41%) 
15 (12%) 
4 (3%) 
12 (10%) 
2s (20%) 
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Table 3. Cardiac Catheterization Data From 125 Patients 
Peak aortic valve gradient (mm Hg) 
Mean aortic valve gradient (mm Hg) 
Aortic valve area (cm’) 
Cardiac output (liters/mitt) 
Extent of coronary disease 
None 
Nonobstructive 
Single vessel 
Multivessel 
I,eft ventricular EF 
Mean EF 
EF <30% 
Before After 
Valvuloplasty Valvuloplasty 
87 2 38 32 + 17 (p < 0.001) 
70 + 26 30 + I3 (p < 0.001) 
0.6 2 0.2 I.0 + 0.3 (p < 0.001) 
4.3 ? I.5 4.6 + 1.3 (p = NS) 
83 (66%) 
I2 (10%) 
I2 (10%) 
18 (14%) 
57 ? 21% 
18 (10%) 
EF = ejection fraction. 
of 15 patients who were moribund before the procedure. 
Within 24 h (early) of the procedure, eight patients, three of 
whom were moribund, died after an adequate dilation. Six of 
these eight patients died because of progressive congestive 
heart failure secondary to severe left ventricular dysfunction 
that did not improve despite successful aortic valvuloplasty. 
The seventh patient died from refractory ventricular arrhyth- 
mias and the eighth patient died as a result of preexisting 
renal failure and hyperkalemia. Two patients died within 30 
days (late) from noncardiac causes (sepsis and renal failure). 
Complications (Table 4). Additional complications in- 
cluded vascular repair, which was required in 3.7% of 
arterial sites entered; in 10 of 12 instances this complication 
Table 4. Hospital Complications After Aortic Valvuloplasty 
in 125 Patients 
No. of 
Patients (%) 
Death 
In cath lab 3 (2.4) 
Early (~24 h) 8 (6.4) 
Late (824 h) 2 (1.6) 
Acute myocardial infarction 2 (1.6) 
Arterial repair 
Incidence per patient I2 (9.6) 
Incidence per entry site I2 of 325 (3.7) 
Aortic regurgitation 2 (1.6)* 
Refractory ventricular arrhythmias I (0.8)’ 
Nemologic deficit 4 (3.2) 
(transient/permanent) 
Blood transfusions 33 (26) 
Before valvuloplasty 3 (3) 
During valvuloplasty 3 (3) 
After valvuloplasty 27 (21) 
No complications 76 (61) 
*These patients required emergency aortic valve replacement. Cath lab = 
cardiac catheterization laboratory. 
was associated with utilization of 12F or 14F femoral 
sheaths. Blood transfusions were required for volume re- 
placement or significant blood loss in 27 patients (21%). In an 
additional six patients, blood was given before or during 
valvuloplasty because of severe chronic anemia. 
Three patients underwent emergency valve replacement: 
two because of acute aortic insufficiency secondary to an 
annular tear (one of these patients survived) and one because 
of refractory ventricular arrhythmia and a mild increase in 
aortic insufficiency, which was considered to be possibly 
secondary to an annular tear. No annular tear was found at 
surgery, and refractory ventricular arrhythmias persisted 
postoperatively. A transient or permanent neurologic deficit 
occurred in four patients (3.2%). Two patients (1.6%) devel- 
oped acute myocardial infarction, one with severe triple 
vessel coronary artery disease and one secondary to distal 
embolization after simultaneous coronary angioplasty of an 8 
year old saphenous vein graft. 
Multivariate predictors of success and mortality (Table 5). 
Univariate analysis showed that multiple variables affected 
mortality. However, when multivariate analysis was ad- 
justed for the presence of clinical and hemodynamic varia- 
bles, only two variables were predictors of successful aortic 
valvuloplasty: the preprocedure left ventricular ejection 
fraction (successful 59 t 18% versus unsuccessful 39 + 26%; 
p < 0.002) and preprocedure cardiac output (successful 4.6 
* 1.5 liters/min versus unsuccessful 3.3 t 0.7 literslmin; p < 
0.05). Clinical congestive heart failure (New York Heart 
Association functional class IV), prevalvuloplasty cardiac 
output and left ventricular ejection fraction were multivari- 
ate predictors of postvalvuloplasty mortality. Surprisingly, 
the pre- and postvalvuloplasty aortic valve areas were not 
associated with an improved survival. 
Follow-up (Table 6). A 100% follow-up (mean time 12 t 
4 months) was obtained for the 112 patients discharged alive 
from the hospital. The cumulative probability of survival at 
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Table 5. Predictors of Mortality After Valvuloplasty in 125 Patients 
Alive Dead 
P Value 
Prevalvuloplasty Variables 
Congestive heart failure 
(class IV) 
Gender 
Male 
Female 
Cardiac output 
(litersimin) 
Age (yr) 
Left ventricular ejection 
fraction (%) 
Aortic valve area (before) 
(cm’) 
Aortic valve area (after) 
(cm? 
(%) 
55% 
51% 
66% 
5.3 ? 1.5 
73 + 13 
64 + 16 
0.57 ? 0.18 
1.03 2 0.33 
(%) 
45% 
49% 
34% 
4.4 t 1.5 
80 + 8 
46 + 20 
0.54 ? 0.18 
1.01 + 0.40 
RR 
5.1 
3.5 
- 
2.0* 
1.w 
1.5t 
- 
- 
Univariate 
<0.002 
10.01 
- 
10.02 
co.07 
co.01 
0.4 
0.7 
Multivariate 
co.01 
co.07 
- 
co.05 
0.9 
co.02 
- 
- 
*Per 1 liter decrease in cardiac output; tper increase in 10 years; Sper decrease in 10 ventricular ejection fraction 
percent points. RR = relative risk. 
12 months was 62 ? 6%; excluding noncardiac deaths it was 
77 ? 5% (Fig. 1). There were 40 late deaths (range 1 to 18 
months) (Table 6) at a mean follow-up time of 6.6 + 5 
months. There were no statistical differences in the timing of 
the deaths when comparing those of cardiac origin (5 t- 5 
months; 26 patients) and of noncardiac origin (8.5 ? 8 
months; 14 patients). The cardiac causes of death during the 
follow-up period were primarily congestive heart failure and 
sudden death (presumably arrhythmia). Noncardiac-related 
causes included pulmonary embolism, stroke, renal failure, 
sepsis, abdominal surgery and cancer. 
Table 6. Follow-up Findings in 112 Patients After 
Aortic Valvuloplasty 
Late deaths 40 (36%) 
Cardiac 26 (23%) 
CHF 16 (14%) 
Sudden death 10 (9%) 
Noncardiac 14 (13%) 
No. of patients alive 72 (64%) 
Symptomatic improvement 57 (51%) 
Recurrence of symptoms 15 (13%) 
AVR due to restenosis 5 (4%) 
Repeat valvuloplasty 10 (9%) 
AVR due to late onset AR 2 (2%) 
Symptomatically improved with restenosis 9 of 12 (75%) 
Valve area before (cm2) 0.8 + 0.3 
Valve area after (cm2) 1.3 2 0.4 
Valve area at f/u cath (cm2) 0.8 ? 0.3 
Symptomatically improved with no restenosis 3 of 12 (25%) 
Valve area before (cm2) 0.7 ? 0.3 
Valve area after (cm*) 1.0 5 0.3 
Valve area at f/u cath (cm2) 1.0 k 0.3 
AR = aortic regurgitation; AVR = aortic valve replacement; CHF = 
congestive heart failure; f/u cath = follow-up cardiac catheterization. 
Hemodynamic follow-up. At last contact, 57 patients 
were symptomatically improved. Recurrence of symptoms 
(mean time 8 ? 3 months) occurred in 15 patients (13%). Ten 
patients underwent repeat valvuloplasty and 5 patients un- 
derwent aortic valve replacement, with catheterization- 
documented restenosis in 14 of them. Valve replacement 
was performed in two patients because of subsequent devel- 
opment of severe aortic insufficiency without restenosis at 8 
and 12 months’ follow-up, respectively. This degree of aortic 
insufficiency was not present at hospital discharge. In addi- 
tion, cardiac catheterization was performed in 12 symptom- 
atically improved patients during follow-up study, with 9 
patients having hemodynamically measured restenosis (that 
is, ~50% loss of the previously gained aortic valve area). 
Figure 1. Life table showing the cumulative probability of survival 
for all patients (PTS) discharged from the hospital and for those with 
cardiac death (CD) only. 
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Table 7. Valve Area at Follow-up Cardiac Catheterization in 26 Patients 
No. of 
Aortic Valve Area (cm*) 
Patients Pre-PTAV Post-PTAV F/u Cath Repeat PTAV 
All patients 26 0.6 f 0.2 I.1 +_ 0.4 0.7 + 0.3 - 
Symptom recurrence 14 0.6 ? 0.2 I.1 +_ 0.4 0.7 + 0.2* - 
Symptom improvement 12 0.6 ? 0.2 I.0 + 0.4 0.9 ? 0.4* 
Repeat PTAV IO 0.5 + 0.2 1.0 ? 0.4 0.7 ? 0.2* 1.0 + 0.3 
*p < 0.03. F/u Cath = follow-up cardiac catheterization; PTAV = aortic valvuloplasty. 
Cardiac catheterization (Table 7) was performed in 26 
patients at a mean follow-up time of 12 + 5 months, with the 
valve area decreasing from 1.07 to 0.73 cm2 (p < 0.03). The 
14 patients who had symptomatic recurrence showed a 
significant decrease in valve area from 1.08 to 0.68 cm2, 
whereas the 12 patients who were still symptomatically 
improved had a less marked, although still significant, de- 
crease from 1.02 cm2 to 0.93 cm2. All asymptomatic patients 
were medically managed. Univariate analysis showed no 
statistical differences among patients with restenosis (repeat 
valvuloplasty, aortic valve replacement and catheterization- 
proved restenosis in 24 patients) and late survivors regarding 
baseline clinical and hemodynamic characteristics. 
Postmortem and surgical observations. Three patients un- 
derwent emergency aortic valve replacement: two patients 
with acute severe aortic insufficiency due to an aortic anulus 
tear extending into the ventricle and the ascending aorta 
(21), whereas the third patient showed no macroscopic 
abnormality. Eleven postmortem examinations showed mac- 
roscopic fractures of valvular calcific nodular deposits, as 
well as microscopic leaflet fractures. No annular tears were 
found. 
Discussion 
Percutaneous aortic valvuloplasty has been offered as an 
alternative to aortic valve replacement in geriatric patients 
with severe aortic stenosis (5) because of the significant 
perioperative valve replacement risks (23-26). The prognosis 
for the patients with successful aortic valve replacement has 
been substantially improved as compared with that of symp- 
tomatic geriatric patients who had not undergone valve 
replacement for whatever reason, primarily because of se- 
vere concomitant medical problems. The mortality rate in 
the latter group was just over 50% at 1 year and approxi- 
mated 65% at 2 years (27,28). Octogenarians (29) who 
underwent aortic valve replacement without coronary artery 
bypass grafting had a 30% early and 18% late mortality rate. 
Furthermore, if the patients had congestive heart failure, 
their operative mortality rate was 62%. 
Present results. In our series of 125 patients, the proce- 
dure was hemodynamically successful, with a final aortic 
valve area >l.O cm2 in 60% of the patients. However, the 
complication rate associated with valvuloplasty was not 
negligible and was not unexpected because 26% of patients 
either had been moribund or had been refused surgery and 
41% were 280 years of age. The in-hospital mortality rate 
was 10.4% (13 of 125 patients), with 6 of the deaths occurring 
in the 15 moribund patients. If these moribund patients were 
excluded from the analysis, the resultant 6.4% mortality rate 
(7 of I10 patients) would be comparable with that achieved 
by surgical valve replacement. Although these six deaths 
were not unexpected, the 60% success rate (nine patients 
were improved and discharged alive) within this moribund 
patient group was encouraging. Aortic valvuloplasty may 
not prolong life (14) but it clearly has improved symptom- 
atology. 
The continuous online measurement of the mixed venous 
oxygen saturation has been an important aspect of the 
valvuloplasty procedure because it has permitted a continu- 
ous assessment of the patient’s hemodynamic status, espe- 
cially the recovery after the compromise created by balloon 
obstruction. Elderly patients with symptomatic aortic steno- 
sis have diminished cardiac and physiologic reserve. The 
return of the patient’s blood pressure to preprocedural 
values when compared with mixed venous oxygen saturation 
has consistently shown that the patient had not recovered 
from the oxygen debt incurred during balloon inflation, a fact 
not appreciated early within this series. 
Correlation of aortic valve area with clinical improvement. 
Justifiable objections to aortic valvuloplasty (30,31) and the 
results (5-10,17), especially those that considered postpro- 
cedural valve areas of <l cm2 a success, were of concern. 
An attempt was made to improve the final aortic valve area 
to approach 1 cm2 employing a multiple balloon technique on 
the grounds that a larger valve area not only would be 
hemodynamically beneficial, but also might have better 
follow-up results when compared with the data in which the 
final valve area approximated 0.75 cm2. However, the mul- 
tivariate analysis was disappointing when it showed that a 
final valve area of >0.9 cm2 did not correlate with improved 
survival, 
In addition, the final valve area or the percent change in 
valve area did not directly correlate with clinical improve- 
ment. In other words, a modest increase in aortic valve area 
(that is, even from 0.4 to 0.6 cm2) could produce a very 
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significant decrease in postprocedural dyspnea, even if crit- 
ical aortic stenosis remained. The reason for this clinical 
improvement remains unclear. A theoretical explanation 
would focus on improved ventricular hemodynamics, with a 
lower end-diastolic volume with its lower wall tension and 
myocardial oxygen consumption. 
Restenosis. The incidence of restenosis after aortic val- 
vuloplasty remains unknown, but might be assumed to be 
between 30% and 60% at a follow-up time of 16 months. 
Doppler echocardiography suggests a very early onset of 
restenosis (14) (that is, a larger valve gradient than ex- 
pected). This postprocedural gradient is still lower than that 
found before the procedure. Twenty-four (34%) of 70 pa- 
tients had hemodynamically proved restenosis regardless of 
their symptoms. If patients with a cardiac death were 
presumed to have restenosis, the overall restenosis rate 
would be a minimum of 46% (50 of 112 patients). 
Sudden death. The initial long-term follow-up study re- 
vealed a disappointingly high incidence of sudden death in 
otherwise hemodynamically stable patients (5 of 10 patients 
with normal left ventricular function). The propensity of 
patients with aortic stenosis to suffer from life-threatening 
arrhythmias (32), even after valve replacement (33), has not 
changed with aortic valvuloplasty. 
Valvuloplasty versus valve replacement. The conclusion 
that valvuloplasty should be offered as an alternative to 
surgical candidates with a relatively good risk profile cannot 
be justified using these data (34) because the valvuloplasty 
morbidity and mortality rates, as well as the restenosis rate, 
remain high. Thus, in any group other than elderly nonsur- 
gical candidates, valvuloplasty must be considered investi- 
gational. This investigation may be warranted because 1) the 
technique has consistently produced an effective valve area 
of >l.O cm’, which is comparable with the effective aortic 
valve area in small prosthetic aortic valves (35); 2) the 
complication rates are relatively low and could lessen with 
technologic advances and more knowledgeable intervention- 
ists; and 3) at least theoretically, valves that were not heavily 
calcified and treated earlier might have a lower restenosis 
rate. 
Limitations of the study. This prospective nonrandom- 
ized study did not address the query of whether good 
surgical candidates should undergo aortic valvuloplasty as 
an alternative technique. However, the observations re- 
ported herein do warrant consideration. The technical ele- 
ments of the procedure changed as the investigators became 
more experienced and used better equipment. Because only 
a small number of follow-up hemodynamic evaluations were 
performed, the follow-up end points of death or valve 
replacement, as well as clinical improvement, require further 
interpretation. In fact, the restenosis rate in asymptomatic 
patients indicated that clinical improvement alone cannot be 
used as a synonym of success. 
Conclusions. Although balloon valvuloplasty has had ini- 
tially good clinical success, follow-up study of the patients 
having this procedure indicates that there is a significant 
incidence of recurrence of restenosis, which should limit its 
application in patients who are considered to be reasonably 
good candidates for surgery. 
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